GNPX
Genprex, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.50
+2.19%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +8.8%
- EBIT
- +8.5%
- EPS
- +71.4%
- Free cash flow
- -16.9%
- Operating cash flow
- -16.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +26.6%
- EBIT
- +26.7%
- Net income
- +23.1%
- EPS
- +93.5%
- Free cash flow
- +10.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026